NCT02344784

Brief Summary

The purpose of this study is to show that Prepulse inhibition test of acoustic startle response is an indicator of objective diagnostic characteristics of attention deficit disorder in children and adolescents. by demonstrating that Prepulse inhibition test of acoustic startle response is impaired in children and adolescents suffering from attention deficit disorder in the relation to the normal function described in the literature. The investigators will try to prove our hypothesis by an experiment that consists of two phases: Phase I (about 25 minutes): The patient will enter the room, will be asked to sit on a chair, and will be asked to look at a computer screen showing silent video of aquarium fish, then the patient will be connected to both the Prepulse inhibition test device and the Galvanic skin response device and pass the tests. Phase II (about 25 minutes): After completion of Phase I, each participant will receive his daily regular dose of methylphenidate and after an hour and a half from taking the drug, will repeat the tests, both the Prepulse inhibition test and the Galvanic skin response test. Duration of the entire experiment is 140 minutes (two hours and twenty minutes).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
46

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2015

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

January 16, 2015

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 26, 2015

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2017

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2017

Completed
Last Updated

August 23, 2016

Status Verified

August 1, 2016

Enrollment Period

2.2 years

First QC Date

January 16, 2015

Last Update Submit

August 22, 2016

Conditions

Keywords

ADDADHDPPI

Outcome Measures

Primary Outcomes (1)

  • Electromyography (EMG) of the right and the left Orbicularis oculi muscle will be recorded during the Prepulse inhibition test

    The outcome measure will be assessed imediatly during each test and the participants will be followed for the whole duration of the experiment, an expected average of 3 hours

Secondary Outcomes (1)

  • Galvanic skin response will be measured by conductivity (Mv) units during the Prepulse inhibition test

    The outcome measure will be assessed imediatly during each test and the participants will be followed for the whole duration of the experiment, an expected average of 3 hours

Interventions

Prepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment

The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test

Also known as: Ritalin

Eligibility Criteria

Age7 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Children and adolescents (age 7 to 17.11 years) who are diagnosed with attention deficit hyperactivity disorder and are under the Medical surveillance of the mental health clinic for children and adolescents at the HaEmek Medical Center- Afula. Patients who meet the criteria for inclusion and exclusion will be offered to participate in the study

You may qualify if:

  • Between the ages of 7-18
  • Diagnosed with attention deficit hyperactivity disorder according to Diagnostic and statistical manual of mental disorders, fifth edition- Clinical diagnostic interview was performed.
  • Receive drug therapy with methylphenidate doses ranging from 0.3 mg / kg to 1 mg / kg.
  • The participant is treated with methylphenidate at least two months prior to the experiment.

You may not qualify if:

  • Autism.
  • Chronic neurological diseases.
  • Developmental delay.
  • Psychotic or major effective disorder (psychotic state now or in the past, schizophrenia, schizoaffective, depression, bipolar disorder)
  • Substance abuse.
  • Mental retardation.
  • Contraindicated for the treatment of methylphenidate.
  • Hearing problems.
  • Pregnancy week 20 and thereafter

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The mental health clinic for children and adolescents at the HaEmek Medical Center

Afula, 18101, Israel

Location

Related Publications (24)

  • Pastor PN, Reuben CA. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. Vital Health Stat 10. 2008 Jul;(237):1-14.

    PMID: 18998276BACKGROUND
  • Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006 Feb;36(2):159-65. doi: 10.1017/S003329170500471X.

    PMID: 16420712BACKGROUND
  • Larson K, Russ SA, Kahn RS, Halfon N. Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics. 2011 Mar;127(3):462-70. doi: 10.1542/peds.2010-0165. Epub 2011 Feb 7.

    PMID: 21300675BACKGROUND
  • Biederman J, Quinn D, Weiss M, Markabi S, Weidenman M, Edson K, Karlsson G, Pohlmann H, Wigal S. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs. 2003;5(12):833-41. doi: 10.2165/00148581-200305120-00006.

    PMID: 14658924BACKGROUND
  • Ornitz EM, Hanna GL, de Traversay J. Prestimulation-induced startle modulation in attention-deficit hyperactivity disorder and nocturnal enuresis. Psychophysiology. 1992 Jul;29(4):437-51. doi: 10.1111/j.1469-8986.1992.tb01717.x.

    PMID: 1410175BACKGROUND
  • Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapoport JL, Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry. 1996 Jan 1;39(1):33-41. doi: 10.1016/0006-3223(95)00101-8.

    PMID: 8719124BACKGROUND
  • Ornitz EM, Russell AT, Hanna GL, Gabikian P, Gehricke JG, Song D, Guthrie D. Prepulse inhibition of startle and the neurobiology of primary nocturnal enuresis. Biol Psychiatry. 1999 Jun 1;45(11):1455-66. doi: 10.1016/s0006-3223(98)00205-4.

    PMID: 10356628BACKGROUND
  • Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001 Jul;156(2-3):234-58. doi: 10.1007/s002130100810.

    PMID: 11549226BACKGROUND
  • Hawk LW Jr, Yartz AR, Pelham WE Jr, Lock TM. The effects of methylphenidate on prepulse inhibition during attended and ignored prestimuli among boys with attention-deficit hyperactivity disorder. Psychopharmacology (Berl). 2003 Jan;165(2):118-27. doi: 10.1007/s00213-002-1235-7. Epub 2002 Nov 1.

    PMID: 12417963BACKGROUND
  • Feifel D, Minassian A, Perry W. Prepulse inhibition of startle in adults with ADHD. J Psychiatr Res. 2009 Jan;43(4):484-9. doi: 10.1016/j.jpsychires.2008.06.004. Epub 2008 Jul 31.

    PMID: 18674783BACKGROUND
  • Hanlon MC, Karayanidis F, Schall U. Intact sensorimotor gating in adult attention deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2009 Jun;12(5):701-7. doi: 10.1017/S1461145708009711. Epub 2008 Dec 2.

    PMID: 19046483BACKGROUND
  • Ashare RL, Hawk LW Jr, Shiels K, Rhodes JD, Pelham WE Jr, Waxmonsky JG. Methylphenidate enhances prepulse inhibition during processing of task-relevant stimuli in attention-deficit/hyperactivity disorder. Psychophysiology. 2010 Sep;47(5):838-45. doi: 10.1111/j.1469-8986.2010.01001.x. Epub 2010 Mar 10.

    PMID: 20233343BACKGROUND
  • Takahashi H, Hashimoto R, Iwase M, Ishii R, Kamio Y, Takeda M. Prepulse inhibition of startle response: recent advances in human studies of psychiatric disease. Clin Psychopharmacol Neurosci. 2011 Dec;9(3):102-10. doi: 10.9758/cpn.2011.9.3.102. Epub 2011 Dec 31.

    PMID: 23429840BACKGROUND
  • Sable JJ, Kyle MR, Knopf KL, Schully LT, Brooks MM, Parry KH, Diamond RE, Flink LA, Stowe R, Suna E, Thompson IA. The Sensory Gating Inventory as a potential diagnostic tool for attention-deficit hyperactivity disorder. Atten Defic Hyperact Disord. 2012 Sep;4(3):141-4. doi: 10.1007/s12402-012-0079-1. Epub 2012 May 27.

    PMID: 22644992BACKGROUND
  • Schulz-Juergensen S, Thiemann A, Gebhardt J, Baumgarten-Walczak A, Eggert P. Prepulse inhibition of acoustic startle and the influence of methylphenidate in children with ADHD. J Atten Disord. 2014 Feb;18(2):117-22. doi: 10.1177/1087054712448960. Epub 2012 Jun 19.

    PMID: 22713361BACKGROUND
  • Holstein DH, Vollenweider FX, Geyer MA, Csomor PA, Belser N, Eich D. Sensory and sensorimotor gating in adult attention-deficit/hyperactivity disorder (ADHD). Psychiatry Res. 2013 Jan 30;205(1-2):117-26. doi: 10.1016/j.psychres.2012.08.013. Epub 2012 Sep 25.

    PMID: 23017654BACKGROUND
  • Kohl S, Heekeren K, Klosterkotter J, Kuhn J. Prepulse inhibition in psychiatric disorders--apart from schizophrenia. J Psychiatr Res. 2013 Apr;47(4):445-52. doi: 10.1016/j.jpsychires.2012.11.018. Epub 2013 Jan 1.

    PMID: 23287742BACKGROUND
  • Feldman HM, Reiff MI. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med. 2014 Feb 27;370(9):838-46. doi: 10.1056/NEJMcp1307215. No abstract available.

    PMID: 24571756BACKGROUND
  • Gebhardt J, Schulz-Juergensen S, Eggert P. Maturation of prepulse inhibition (PPI) in childhood. Psychophysiology. 2012 Apr;49(4):484-8. doi: 10.1111/j.1469-8986.2011.01323.x. Epub 2011 Dec 16.

    PMID: 22176532BACKGROUND
  • Swerdlow NR, Braff DL, Geyer MA. Cross-species studies of sensorimotor gating of the startle reflex. Ann N Y Acad Sci. 1999 Jun 29;877:202-16. doi: 10.1111/j.1749-6632.1999.tb09269.x.

    PMID: 10415651BACKGROUND
  • Grim PF. A sustained attention comparison of children and adults using reaction time set and the GSR. J Exp Child Psychol. 1967 Mar;5(1):26-38. doi: 10.1016/0022-0965(67)90074-4. No abstract available.

    PMID: 6038515BACKGROUND
  • Okkesim S, Kara S, Kaya MG, Asyali MH. Analysis of coronary angiography related psychophysiological responses. Biomed Eng Online. 2011 Aug 11;10:71. doi: 10.1186/1475-925X-10-71.

    PMID: 21834993BACKGROUND
  • Kumari V, Fannon D, Geyer MA, Premkumar P, Antonova E, Simmons A, Kuipers E. Cortical grey matter volume and sensorimotor gating in schizophrenia. Cortex. 2008 Oct;44(9):1206-14. doi: 10.1016/j.cortex.2007.11.007. Epub 2008 Jan 20.

    PMID: 18761134BACKGROUND
  • Molina V, Montes C, Tamayo P, Villa R, Osuna MI, Perez J, Sancho C, Lopez-Albuquerque T, Cardoso A, Castellano O, Lopez DE. Correlation between prepulse inhibition and cortical perfusion during an attentional test in schizophrenia. A pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Feb 1;33(1):53-61. doi: 10.1016/j.pnpbp.2008.10.011. Epub 2008 Oct 30.

    PMID: 19000732BACKGROUND

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Interventions

Methylphenidate

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PhenylacetatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • AVRAHAM AVITAL

    Technion, Israel Institute of Technology

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

January 16, 2015

First Posted

January 26, 2015

Study Start

January 1, 2015

Primary Completion

March 1, 2017

Study Completion

June 1, 2017

Last Updated

August 23, 2016

Record last verified: 2016-08

Locations